Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Francesca Palandri et al.|Cancer|2025Cited by 10
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Francesco Cavazzini et al.|Cancer|2024Cited by 10
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case seriesFrancesca Palandri, Mario Tiribelli, Filippo Branzanti et al.|British Journal of Haematology|2024Cited by 6
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Valerio De Stefano, Massimo Breccia et al.|Leukemia|2025Cited by 6
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Filippo Branzanti et al.|Cancer|2025Cited by 5